Dear readers,
We are glad to announce the launch of our new website, There you will continue to have access to the full content of the Sharecast newswire, alongside an improved and expanded suite of market data and research tools for both the UK and the main international markets. As a first step in the transition to the new site, over coming days and weeks the news and data pages on will redirect you towards the new website which we earnestly hope you will find even more useful than the current service. Should anyone like to comment or provide constructive criticism on the new layout or what features they would like to see added or deleted, do please send us an e-mail to Lastly, of course, we wish to express our heartfelt gratitude for your support and encouragement over the years as we continued to grow and expand the service.
Very best,


PureTech signs deal with Roche for chronic disease treatments

Company News

PureTech signs deal with Roche for chronic disease treatments

Fri, 20 July 2018

(Sharecast News) - PureTech Health has announced a deal with Roche that could result in the Swiss drug giant paying the company more than $1bn (£769m) linked to PureTech's treatments for cancer and other chronic diseases.

The London-listed company said Roche would pay it up to $36m in upfront payments, research support and early preclinical milestones. PureTech will also be eligible for "development milestone payments of over $1bn and additional sales milestones and royalties for an undisclosed number of products".

PureTech shares rose 11% to 151.10p at 08:59 BST.

PureTech, which is based in Boston, Massachusetts, is developing milk-derived products that allow patients to take oral versions of complex payloads such as nucleic acids, peptides and small molecules for the treatment of diseases. Its products concentrate on links between the brain, gut and immune system to treat diseases that sap the majority of health spending.

Daphne Zohar, PureTech's chief executive, said: "We are excited to accelerate the development of this promising technology from our internal lymphatic and immune cell trafficking programmes. The expertise and resources that Roche is bringing to the collaboration will help us to potentially address one of the biggest challenges in oligonucleotide-based therapeutic development: oral administration of nucleic acids."